MacroGenics, Inc. (MGNX)
| Market Cap | 248.52M +164.4% |
| Revenue (ttm) | 157.08M +2.0% |
| Net Income | -70.36M |
| EPS | -1.11 |
| Shares Out | 63.56M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 559,879 |
| Open | 4.270 |
| Previous Close | 4.250 |
| Day's Range | 3.870 - 4.290 |
| 52-Week Range | 1.185 - 4.640 |
| Beta | 1.20 |
| Analysts | Buy |
| Price Target | 6.75 (+72.41%) |
| Earnings Date | May 13, 2026 |
About MGNX
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MG... [Read more]
Financial Performance
In 2025, MacroGenics's revenue was $149.50 million, a decrease of -0.31% compared to the previous year's $149.96 million. Losses were -$74.62 million, 11.4% more than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for MGNX stock is "Buy." The 12-month stock price target is $6.75, which is an increase of 72.41% from the latest price.
News
MacroGenics Transcript: Stifel 2026 Targeted Oncology Virtual Forum
Significant non-dilutive capital from royalty and manufacturing deals extends runway through 2028, enabling robust investment in a diversified oncology pipeline. Key clinical updates for ADC and bispecific programs are expected in 2024, with a focus on innovation and strategic partnerships.
MacroGenics to Participate in the Stifel 2026 Virtual Targeted Oncology Forum
ROCKVILLE, MD, May 14, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, ...
MacroGenics reports Q1 EPS (58c), consensus (55c)
Reports Q1 revenue $20.78M, consensus $15.24M. “We are very pleased to report a strong start to the year, building on the momentum generated in 2025. These results reflect our team’s…
MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation
ROCKVILLE, Md., May 13, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treat...
MacroGenics Quarterly report: Q1 2026
MacroGenics has published its Q1 2026 quarterly earnings report on May 13, 2026.
MacroGenics Earnings release: Q1 2026
MacroGenics released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
MacroGenics to sell GMP manufacturing operations to Bora for $122.5M upfront
MacroGenics (MGNX) and Bora Pharmaceuticals announced that they had entered into a definitive agreement in which MacroGenics will sell its good manufacturing practice, or GMP, drug substance manufactu...
MacroGenics to Sell GMP Manufacturing Operations to Bora Pharmaceuticals
•MacroGenics to receive $122.5 million upfront payment from Bora upon closing•Transaction includes transfer of manufacturing site, CDMO operations and associated personnel to Bora
MacroGenics trading halted, news pending
16:25 EDT MacroGenics (MGNX) trading halted, news pending
MacroGenics, Sagard enter expanded Zynyz royalty purchase agreement
MacroGenics (MGNX) announced that it entered into an expanded royalty purchase agreement with Sagard in exchange for a capped royalty interest on future global net sales of Zynyz. MacroGenics and…
MacroGenics and Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement
• MacroGenics receives $60 million cash payment from Sagard Healthcare Partners (Sagard), with the potential to receive an additional near-term sales-based milestone of up to $20 million • MacroGenics...
MacroGenics Proxy statement: Proxy filing
MacroGenics filed a proxy statement on April 22, 2026, providing details for shareholder voting and corporate governance matters.
MacroGenics price target raised to $6 from $4 at Barclays
Barclays raised the firm’s price target on MacroGenics (MGNX) to $6 from $4 and keeps an Overweight rating on the shares. The firm adjusted ratings and targets in the small…
MacroGenics upgraded to Buy at B. Riley after deal for Tubulus
B. Riley upgraded MacroGenics (MGNX) to Buy from Neutral with a $9 price target. Following the Gilead (GILD) deal for Tubulus earlier this week, the firm put together a proprietary…
MacroGenics upgraded to Buy from Neutral at B. Riley
B. Riley upgraded MacroGenics (MGNX) to Buy from Neutral with a $9 price target
MacroGenics says FDA removes partial clinical hold on Phase 2 LINNET study
MacroGenics (MGNX) announced that the U. S. FDA has removed the partial clinical hold on the company’s Phase 2 LINNET study of lorigerlimab, an investigational, bispecific DART molecule that targets…
FDA Removes Partial Clinical Hold on MacroGenics' LINNET Study
• Plan to resume enrollment in clinical study of lorigerlimab in gynecologic cancers • On track to provide mid-2026 program update ROCKVILLE, MD, April 08, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc...
MacroGenics Proxy statement: Proxy filing
MacroGenics filed a proxy statement on April 8, 2026, providing details for shareholder voting and corporate governance matters.
MacroGenics Proxy statement: Proxy filing
MacroGenics filed a proxy statement on April 8, 2026, providing details for shareholder voting and corporate governance matters.
MacroGenics Transcript: Barclays 28th Annual Global Healthcare Conference
The session highlighted a robust oncology pipeline with three ADCs advancing, including MGC026 and MGC028, and a dual checkpoint inhibitor, lorigerlimab, facing a partial clinical hold. Strong partnerships and non-dilutive capital position the company for key 2026 milestones.
MacroGenics Transcript: The Citizens Life Sciences Conference 2026
Leadership sharpened focus on capital allocation and pipeline inflection points, with a strong cash runway through 2027. ADC and bispecific programs advance with promising safety and efficacy, while partnerships with Gilead, Incyte, and Sanofi offer substantial milestone and royalty potential.
MacroGenics Transcript: Leerink Global Healthcare Conference 2026
Management is prioritizing key pipeline assets and operational efficiency, with major clinical updates for lorigerlimab and ADC programs expected by mid-2026. Strong business development and a robust cash position support ongoing innovation and future milestones.
MacroGenics price target raised to $4 from $3 at Barclays
Barclays raised the firm’s price target on MacroGenics (MGNX) to $4 from $3 and keeps an Overweight rating on the shares following the Q4 report. The firm sees the company’s…
MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures
ROCKVILLE, Md., March 09, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the tre...